SGLT2 inhibitors and atrial fibrillation

trial fibrillation (AF) is the most common sustained cardiac arrhythmia, with a lifetime risk of around 25% in those over 40 years of age (Lloyd-Jones et al, 2004). People with diabetes have a roughly 40% greater risk of developing AF than those without diabetes (Huxley et al, 2011). AF is an independent risk factor for stroke and heart failure, and is associated with more severe strokes due to the large clots that embolise from the heart (Lin et al, 1996; Berg et al, 2019).

A recent study by <u>Papazoglou et al (2021)</u> has highlighted the increased risk associated with comorbid diabetes in people with AF. In a substudy of the MISOAC-AF (Motivational Interviewing to Support Oral AntiCoagulation Adherence in patients with non-valvular AF) trial, 1140 people with AF, of whom a third had diabetes, were followed for a median of 2.6 years. Over that time frame, 36% of the cohort died, mostly from cardiovascular causes. In particular, people with diabetes were significantly more likely to die from cardiovascular causes than those without the condition (34.9% vs 23.5%; *P*<0.001).

After adjustment for other risk factors, diabetes remained a significant predictor of adverse outcomes, increasing the risk of all-cause death by 44%, cardiovascular death by 44%, cardiac arrest by 73% and stroke by 87%.

Glycaemic control significantly affected mortality, with each 11 mmol/mol (1.0%) increase almost doubling the risk of all-cause and cardiovascular mortality, and a linear association between HbA1c and death. The risk of death was significantly lower at HbA_{1c} levels under 44 mmol/mol (6.2%). Other factors associated with survival were age; estimated glomerular filtration rate; and use of beta-blockers, digoxin, angiotensinconverting enzyme inhibitors, angiotensin receptor blockers and novel oral anticoagulants after discharge.

These findings concur with those of other AF studies, which showed a nearly doubled risk of mortality in people with AF and comorbid diabetes compared to those without diabetes. The results highlight the high personal costs associated with AF, particularly in those with diabetes, and emphasise the urgent need to manage both glycaemia and other cardiovascular risk factors in people who develop AF.

A role for SGLT2 inhibitors?

Another study, published in the same issue of *Cardiovascular Diabetology*, provides evidence that sodium–glucose cotransporter 2 (SGLT2) inhibitors may be effective in preventing new-onset AF in people with type 2 diabetes. Using a data-mining approach, <u>Bonora et al (2021)</u> searched the US Food and Drug Administration's adverse event reporting system to compare rates of AF between SGLT2 inhibitors and other glucose-lowering drugs. Between 2014 and the end of 2019, there were 62 098 adverse events in which an SGLT2 inhibitor was suspect or concomitant, compared with 642 031 reports involving other glucose-lowering drugs.

The reporting of AF was significantly lower with SGLT2 inhibitors than with other diabetes drugs (4.8 versus 8.7 events per 1000 reports; P<0.001), implying a potential protective effect. The results were consistent when a number of sensitivity analyses were carried out to exclude effects of other treatments, diabetes severity, kidney disease and cardiovascular disease as treatment indications, and dilution by other SGLT2 inhibitor adverse events such as urinary tract infections and diabetic ketoacidosis.

These real-world findings support the results from clinical and cardiovascular outcome trials and observational studies suggesting that SGLT2 inhibitors can prevent AF in people with type 2 diabetes (Li et al, 2020; Ling et al, 2020; Zelniker et al, 2020; Okunrintemi et al, 2021).

| ORIGINAL INVESTIGATION | Open Acces |
|---|---|
| Prognostic significance of diabetes mellitus | |
| Andreas S. Papaeoglou 'B. Anastasios Kartas 'B. Adh Eleni Vitana' D. Dimitrios V. Moysidis 'D. Evangelos Al Anastasion Papamatasiou', Evangelos Liampan', Mic Hasalambos Karvounis', Apostolos Takus ^{1,3} and Geo | rivos ² , Georgios Kotzampasis ¹ , Amaila Baroutidou ¹ , hail Botis ¹ , Efitratios Karagiannidis ¹ <mark>O,</mark> Nikolaos Stalikas ¹ G |
| (eA) Cyclet outcome is parent with multi failuble Methods: This respective chort used (included part ondary dispose) of AF from Downhow 2015 (through) have close (self) wave included for the heydnary cust of cardioacular (C) (including and the complete iso analyzer own performed to a close the ownhol in a close and morning among partners with AF and Penktris is that 100 AF partners were the 25 system (44.02) July partners due The presence of the 25 system (44.02) July partners due The presence of the 25 system (44.02) July partners due The presence of the 25 system (44.02) July partners due The presence of the 25 system (44.02) July partners due The presence of the 25 system (40.02) July partners due The presence | lens who were recently hospitalised with a primary or use- and XH & Rajaham-Meine Crueder and Care apprecian adjusted arms of all cause montality and for the secondary continence one and CH data the transportational Companying via regression we fail of ensist, major beleding, W-crisif-hospitalizations are cause models were thread to investigate associations of d DM. on X23 (CLAB) and DM. During a median trillow-up of here associated with a higher risk of all-cause montality montality (all-M). Sp(VeC1107-114), adden cardiac |
| talization or CV death (μ -R = 1.27, 95% CI 1.06–1.53). In podieve linear association between HRA1 clevels and or il increased all-cause montality, and values < 6.2% pred Conclusion: The presence of CNI on top-of AF was as | adated with subtrantially increased risk for all-cause or CV |
| | IbA1c levels lower than 6.2% were independently aloted tool could be associated with better clinical outcomes in AF |
| Keywords: Anial fibrillation, Diabetes mellitus, Glycate | dhemoglobin, HbA/c, Stroke, Mortality |
| Companions generals-inductory for Description of Conting (VIII) Science (Viewel America memory of Description (S. Konkil), USAN Description (Second M. M. Alexandrow Science (S. Konkil), USAN Description (Second M. M. M | Background Both artist BackBation (AF) and diabetes mellion (D are model) conditions that nonsideys affect weats populations at an optichesis ratio. These diseases have be evalued into a server health therat and a corely gid health bundles. AF is the smoot chinically important o diam elythem disorders, to providence will have rises to diam elythem disorders. The providence will have rises to |
| BMC | nal ander a Cautan Carrenne. Instanten til Hannational Carron, och Apprentis och dare och ange medlema Hanna, aktorg angen gåga appropriate Steringen av Berletiger Carronne Karron, av Hanna Hanna av Berger, av Berger, av Berger, av Hanna Hanna ett al påge som |

Prognostic significance of diabetes mellitus in patients with atrial fibrillation. Available at: https://doi.org/10.1186/s12933-021-01232-7



SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. Available at: https://doi.org/10.1186/s12933-021-01243-4

Citation: SGLT2 inhibitors and atrial fibrillation. *Journal of Diabetes Nursing* **25**: JDN188



Read more online

How to use SGLT2 inhibitors safely and effectively

Part of the "How to" series, this updated quick reference guide presents the latest guidance on the safe and effective use of SGLT2 inhibitors.

Diabetes & Primary Care 23: 5–7

Click here to access

The authors have previously proposed a number of mechanisms by which SGLT2 inhibitors might reduce the risk of AF (Bonora et al, 2020), many of which may also explain the drug class's known effects on reducing heart failure.

Conclusion

The precise reasons for the association between AF and diabetes remain unexplained. However, it is encouraging that a widely used glucose-lowering drug class can potentially reduce the burden of this common diabetes comorbidity. Above all, these studies remind us of the need to consider the cardiovascular aspects of diabetes management.

- Bonora BM, Raschi E, Avogaro A, Fadini GP (2021) SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. *Cardiovasc Diabetol* **20**: 39
- Huxley RR, Filion KB, Konety S, Alonso A (2011) Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol* **108**: 56–62
- Li WJ, Chen XQ, Xu LL et al (2020) SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with metaanalysis of 16 randomized controlled trials. *Cardiovasc Diabetol* **19**: 130
- Lin HJ, Wolf PA, Kelly-Hayes M et al (1996) Stroke severity in atrial fibrillation. The Framingham Study. *Stroke* **27**: 1760–4
- Ling AW, Chan CC, Chen SW et al (2020) The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. *Cardiovasc Diabetol* **19**: 188
- Lloyd-Jones DM, Wang TJ, Leip EP et al (2004) Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* **110**: 1042–6
- Okunrintemi V, Mishriky BM, Powell JR, Cummings DM (2021) Sodium–glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. *Diabetes Obes Metab* 23: 276–80
- Papazoglou AS, Kartas A, Samaras A et al (2021) Prognostic significance of diabetes mellitus in patients with atrial fibrillation. *Cardiovasc Diabetol* **20**: 40
- Zelniker TA, Bonaca MP, Furtado RHM et al (2020) Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. *Circulation* **141**: 1227–34

Berg DD, Wiviott SD, Scirica BM et al (2019) Heart failure risk stratification and efficacy of sodium–glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus. *Circulation* 140: 1569–77

Bonora BM, Avogaro A, Fadini GP (2020) Extraglycemic effects of SGLT2 Inhibitors: a review of the evidence. *Diabetes Metab Syndr Obes* **13**: 161–74